Levilimab - Biocad
Alternative Names: BCD 089; IlsiraLatest Information Update: 14 Apr 2023
Price :
$50 *
At a glance
- Originator Biocad
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections; Rheumatoid arthritis
Most Recent Events
- 07 Dec 2022 Phase-III clinical trials in Rheumatoid arthritis in Russia (IV) (NCT05800327)
- 07 Dec 2022 Biocad initiates a phase III trial in Rheumatoid arthritis in Russia (SC) (NCT05800327)
- 24 Jun 2022 No development reported - Phase-III for Rheumatoid arthritis (Adjunctive treatment) in Belarus (SC)